Clinical Trial: A Trial for Patients With Gestational Trophoblastic Disease
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Phase II Trial of Pemetrexed (Alimta) in the Treatment of Recurrent or Persistent Low Risk Gestational Trophoblastic Tumor
Brief Summary: This phase II study is evaluating the activity of Pemetrexed in patients diagnosed with low risk Gestational Trophoblastic Tumor (GTT) that have failed prior treatment.
Detailed Summary:
Sponsor: Eli Lilly and Company
Current Primary Outcome: To determine the activity of Pemetrexed in failed low risk Gestational Trophoblastic Tumor (GTT) patients
Original Primary Outcome: Same as current
Current Secondary Outcome: To determine the toxicity of Pemetrexed in failed low risk Gestational Trophoblastic Tumor (GTT) patients
Original Secondary Outcome: Same as current
Information By: Eli Lilly and Company
Dates:
Date Received: September 12, 2005
Date Started: July 2006
Date Completion:
Last Updated: August 7, 2007
Last Verified: August 2007